Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 10Sarcoma 3Dermatologic 2Thoracic 1Lymphoid 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Non-melanoma Skin Cancer 1Melanoma 1Breast Neoplasms 1

Interventions

pembrolizumab 157Nivolumab 132Ipilimumab 77Cyclophosphamide 46Specimen Handling 44Magnetic Resonance Spectroscopy 39cemiplimab 35Biopsy 31fludarabine 28trametinib 24relatlimab 24binimetinib 23Interleukin-2 21fludarabine phosphate 20dabrafenib 20atezolizumab 20Radiotherapy 20Opdualag 19Radiosurgery 18CTLA-4 Antigen 18encorafenib 17aldesleukin 17Blood Specimen Collection 17avelumab 14Immunoglobulin G 14Disulfides 13lenvatinib 11Bevacizumab 11lifileucel 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Eflornithine × Dermatologic × 1 year × Clear all
NCT07287917 2026-05-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Aminex Therapeutics, Inc.

Phase 1/2 Recruiting
92 enrolled
BreastDermatologic

Breast Neoplasms, Melanoma

NCT04091022 2025-12-17

Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer

University of Alabama at Birmingham

Phase 2 Completed
64 enrolled
Dermatologic

Non-melanoma Skin Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡